BioXcel Therapeutics

87 articles about BioXcel Therapeutics

• BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

  10/25/2023

  BioXcel Therapeutics, Inc. today announced positive findings from an independent third party audit of the data from a single site1 in its TRANQUILITY II Phase 3 trial.

• BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

  10/4/2023

  BioXcel Therapeutics, Inc. today provided an update on recent developments with its late-stage clinical programs as well as its patent portfolio for IGALMI™ (dexmedetomidine) sublingual film.

• BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

  8/14/2023

  BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the second quarter ended June 30, 2023, and a strategic reprioritization to strengthen its focus and significantly reduce operating expenses.

• 

  BioXcel’s Positive Alzheimer’s Agitation Data Overshadowed by Principal Investigator Fabrications

  6/29/2023

  The company Thursday reported positive topline results for a Phase III trial of its Alzheimer’s-related agitation treatment, while also disclosing improprieties by a principal investigator.

• BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

  6/29/2023

  BioXcel Therapeutics, Inc. announced positive topline results for TRANQUILITY II, a Phase 3 trial of BXCL501, the Company’s proprietary, orally dissolving film formulation of dexmedetomidine under investigation for the acute treatment of Alzheimer’s disease-related agitation.

• BioXcel Therapeutics to Participate at Two Upcoming June 2023 Investor Conferences

  6/1/2023

  BioXcel Therapeutics, Inc. announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in fireside chats at two upcoming investor conferences.

• BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights

  5/8/2023

  BioXcel Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2023, and provided an update on key strategic initiatives.

• BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023

  4/24/2023

  BioXcel Therapeutics, Inc. today announced that it will release its first quarter 2023 financial results on Monday, May 8, 2023 before the open of the U.S. financial markets.

• OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

  3/14/2023

  OnkosXcel Therapeutics, LLC announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock following its conversion into a corporation.

• BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

  3/9/2023

  BioXcel Therapeutics, Inc today announced its financial results for the fourth quarter and full year ended Dec. 31, 2022 and provided an update on key strategic initiatives.

• BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

  2/23/2023

  BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023 before the open of the U.S. financial markets.

• BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium

  2/13/2023

  BioXcel Therapeutics, Inc. today announced full data from its Phase 2a trial of BXCL701, the Company's investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer.

• BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer

  2/8/2023

  BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced that it will host a Key Opinion Leader (KOL) Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET.

• 

  BioXcel Spinout Posts Promising Results in Rare Prostate Cancer

  1/11/2023

  BioXcel Therapeutics subsidiary OnkosXcel announced positive Phase II results in patients with small cell neuroendocrine metastatic castration-resistant (SCNC) prostate cancer.

• BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

  1/11/2023

  BioXcel Therapeutics, Inc. today announced promising top-line data from its Phase 2 trial of BXCL701.

• BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

  12/22/2022

  BioXcel Therapeutics, Inc. today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present corporate updates and anticipated milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 9:45 a.m. PST.

• BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

  12/19/2022

  BioXcel Therapeutics, Inc. today announced that the first patient has been dosed in the pivotal Phase 3 TRANQUILITY III trial of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, orally dissolving film, under investigation for the acute treatment of agitation in patients with Alzheimer’s disease (AD).

• BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference

  12/1/2022

  BioXcel Therapeutics, Inc., announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 1:45 p.m. Eastern Time.

• BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

  11/30/2022

  BioXcel Therapeutics, Inc. today announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, orally dissolving film, for agitation associated with bipolar I or II disorder or schizophrenia.

• BioXcel Therapeutics to Present at Two Upcoming November 2022 Investor Conferences

  11/14/2022

  BioXcel Therapeutics, Inc. announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in fireside chats at two upcoming investor conferences.